RELISTOR is the first agent that targets the underlying cause of opioid-induced constipation (OIC) without impacting opioid-mediated analgesic effects on the central nervous system.1

RELISTOR decreases the constipating effects of opioids in patients with advanced illness
who are receiving palliative care¹

• RELISTOR is the first selective peripherally acting mu–opioid receptor antagonist displacing opioid binding in
  tissues such as the gastrointestinal tract¹

RELISTOR does not diminish the central analgesic effects of opioids¹

• RELISTOR has a unique molecular structure that restricts it from crossing the blood-brain barrier¹
• In clinical studies, RELISTOR demonstrated:
  • No clinically relevant changes in pain scores from baseline¹
  • No central opioid withdrawal³

Important Safety Information for RELISTOR

• RELISTOR is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction
• If severe or persistent diarrhea occurs during treatment, advise patients to discontinue therapy with RELISTOR and consult their physician
• Rare cases of gastrointestinal (GI) perforation have been reported in advanced illness patients. Use RELISTOR with caution in patients with known or suspected lesions of the GI tract
• Use of RELISTOR has not been studied in patients with peritoneal catheters
• The most common adverse reactions reported with RELISTOR compared with placebo in clinical trials were abdominal pain (28.5% vs 9.8%), flatulence (13.3% vs 5.7%), nausea (11.5% vs 4.9%), dizziness (7.3% vs 2.4%), diarrhea (5.5% vs 2.4%), and hyperhidrosis (6.7% vs 6.5%)
• Safety and efficacy of RELISTOR have not been established in pediatric patients

Please see the full Prescribing Information.

Next: Efficacy »